| DATE | August 25th, 2025 | |
Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
Corbion, the global sustainable ingredients company based in Amsterdam, and BRAIN Biotech AG, headquartered in Zwingenberg, Germany, have reached agreement to collaborate in the development of novel biobased antimicrobial compounds and its derivatives. This collaboration will accelerate Corbion’s efforts to deliver enabling preservation capabilities to food manufacturers that also resonate with consumers looking for food products based on natural ingredients.
“At Corbion, advancing the state of the art in nature-based ingredient technologies, proving and expanding on their value and efficacy, is essential to preserving what matters,” said Domenico Vulcano, Vice President of Global Innovation at Corbion. “One of the ways we continue to strengthen our investment in innovation is through establishing partnerships with other experts like those at BRAIN Biotech. We believe this kind of collaboration will help us bring the next paradigm-changing breakthroughs to market sooner.”
BRAIN Biotech AG brings to the collaboration expertise in specialty enzyme technology, microbial strain development, and bioprocess development. Additionally, it operates as a technology licensing company. Corbion brings advanced knowledge of food systems and biobased preservation technologies, intimate customer and industry-specific insights, and leading-edge piloting and scale-up capabilities.
“We are very pleased to partner with Corbion in expanding what’s possible with sustainable, bio-based solutions,” said Dr. Martin Langer, Managing Director & Executive Vice President at BRAIN Biotech AG. “We see a very strong affinity between our team at BRAIN and our collaborators at Corbion. Given our respective strengths, shared vision, and complementary areas of expertise, we expect this to be a fruitful collaboration that will deliver real impact for the world’s food manufacturers.”
For more information, please contact:
Press:
Ashley Robertson, Director Global Marketing and Communications Corbion
Ashley.Robertson@corbion.com
Dr. Stephanie Konle, PR & Corporate Communications BRAIN Biotech AG
stk@brain-biotech.com
Analysts and investors:
Alex Sokolowski, Head of Investor Relations Corbion
+31(0)6 46941365
Martina Schuster, Investor Relations BRAIN Biotech AG
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com
Background information:
Corbion
Corbion is a sustainable ingredients company dedicated to preserving what matters, including food and food production, health, and the planet. We specialize in lactic acid, lactic acid derivatives, food preservation solutions, functional blends, and algae ingredients, using our deep application and product knowledge to propel nature’s ingenuity through science. With more than a century of experience, we continue working side-by-side with our customers to make our cutting-edge technologies work for them. Leveraging our advanced capabilities in fermentation and preservation technology, we help customers differentiate their products in diverse markets ranging from food and animal nutrition to home & personal care, pharmaceuticals, electronics, medical devices, and bioplastics. In 2024, Corbion generated annual sales of € 1,332.0 million with a workforce of 2,399 FTEs. Corbion is listed on Euronext Amsterdam. For more information: www.corbion.com
BRAIN Biotech AG
BRAIN Biotech AG is a leading group of companies in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio.
The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA.
BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com.
